August 07, 2026

EULAR Updates Guidance for PMR, LVV

The revised guidance supports early and definitive diagnosis, structured glucocorticoid tapering, and targeted therapies for selected patients.

MDSpire News

August 06, 2026

Povorcitinib in Phase 3 Hidradenitis Suppurativa Trials

Both oral doses met the primary endpoint at week 12, with long‐term efficacy summarized descriptively through week 54.

MDSpire News

August 04, 2026

Uncovering Persistent Pain Pattern in Gout

A cross‐sectional study found that one‐third of patients reported a constant pain pattern, with earlier gout onset, greater activity limitation, and anxiety or depression independently associated with persistent symptoms.

MDSpire News

July 31, 2026

Secukinumab Trial Targets Relapsed Polymyalgia Rheumatica

Phase 3 findings address remission durability and glucocorticoid use in patients who relapsed during prednisone tapering.

MDSpire News

July 29, 2026

Can Statin Muscle Risk Be Predicted?

Researchers developed and externally validated a prediction model estimating 1-, 5-, and 10-year risks of serious muscle disorders among patients potentially eligible for statin therapy.

MDSpire News

July 29, 2026

Bearing Combinations May Improve THA Survival

A linked UK registry analysis found lower long-term reoperation rates with select highly crosslinked polyethylene bearing combinations following total hip arthroplasty.

MDSpire News

July 24, 2026

May Kaplan Fiber Injury Signal Greater Knee Instability?

Magnetic resonance imaging showed that Kaplan fiber injury was associated with greater anterior tibial subluxation following anterior cruciate ligament injury, suggesting that the finding may help identify patients with greater knee instability.

MDSpire News

July 23, 2026

GRAPPA, EULAR Criteria May Identify Complex PsA

Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.

MDSpire News

July 22, 2026

Ixekizumab May Improve Early Response After Secukinumab Failure

A real-world cohort found faster early skin responses with ixekizumab than with guselkumab or ustekinumab following secukinumab treatment failure, while all three biologics demonstrated favorable safety.

MDSpire News

July 22, 2026

Medical Oddities: When AI Meets the Afterlife

Ghosts, germs, B cells, and brews—this week's research is anything but ordinary.

MDSpire News